CardioResus Evolution and Mission Statement

CardioResus Limited was established in  December 2025 with a commitment to advancing access to life-saving cardiac care.

In the same month, the company signed an agreement to acquire the global patents, all intellectual property, and selected physical assets of a medical device business that had developed a personal automated external defibrillator (AED), with more than 25,000 units sold globally.  This AED is the smallest, lightest and easiest to use defibrillator ever approved for sale.

The acquisition was completed in April 2026, marking an important milestone in the company’s evolution. CardioResus has raised $2.3 million as an Australian unlisted Public Company with over 90 shareholders from investors who recognised the product’s potential and the company’s vision.

CardioResus is now focused on improving its patented defibrillator technology, with the next-generation device planned for release in 2027.

CardioResus Mission Statement

CardioResus is committed to transforming access to emergency cardiac care through innovative personal-use defibrillators.

Our mission is to deliver compact, lightweight, and highly portable devices that enable immediate intervention in critical moments.

We strive to make life-saving automated external defibrillation more accessible by offering the most affordable solution globally.

Through innovation, reliability, and accessibility, we aim to address the urgent global challenge of sudden cardiac arrest.

At CardioResus, we are dedicated to empowering individuals and communities with the means to save lives.